Log on / register
Feedback | Support | My details
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI
Breast Cancer Res 2007, 9:R50
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
The ERBB3 receptor in cancer and cancer gene therapy.
Sithanandam G, Anderson LM
Cancer Gene Ther 2008 Jul, 15:413-48
 [PubMed Central] [PubMed] [Related articles]
2.
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, de Cremoux P, Stenvang J, Lykkesfeldt AE
Breast Cancer Res Treat 2009 Mar, 114:263-75
 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 1 article in BioMed Central


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.